Pasar al contenido principal

ANALISIS MULTIFACTORIAL DE LA RESISTENCIA A FARMACOS ANTI-TUMORALES EN SARCOMAS USANDO MODELOS DERIVADOS DE PACIENTES

PID2019-106666RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION E INNOVACION BIOSANITARIA EN EL PRINCIPADO DE ASTURIAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

  • Estupiñán, Óscar
  • Rey, Verónica
  • Tornín, Juan
  • Murillo, Dzohara
  • Gallego, Borja
  • Huergo, Carmen
  • Blanco Lorenzo, Verónica
  • González Meana, M. Victoria
  • Rodríguez Pérez, Aida
  • Moris, Francisco
  • González Miranda, Jessica
  • Ayllón, Verónica
  • Ramos-Mejía, Verónica
  • Bigas Salvans, Anna
  • Rodríguez, René
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor cells, including cancer stem cell subpopulations (CSC), in sarcomas. In transcriptomic and protein expression analyses, we identified NOTCH1 signaling as one of the main pro-stemness pathways repressed by EC-8042 in osteosarcomas. Overexpression of NOTCH-1 resulted in a reduced anti-tumor effect of EC-8042 in CSC-enriched 3D tumorspheres cultures. On the other hand, the depletion of the NOTCH-1 downstream target HES-1 was able to enhance the action of EC-8042 on CSCs. Moreover, HES1 depleted cells failed to recover after treatment withdrawal and showed reduced tumor growth potential in vivo. In contrast, mice xenografted with NOTCH1-overexpressing cells responded worse than parental cells to EC-8042. Finally, we found that active NOTCH1 levels in sarcoma patients was associated to advanced disease and lower survival. Overall, these data highlight the relevant role that NOTCH1 signaling plays in mediating stemness in osteosarcoma. Moreover, we demonstrate that EC-8042 is powerful inhibitor of NOTCH signaling and that the anti-CSC activity of this mithramycin analog highly rely on its ability to repress this pathway., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grant PID2019–106666RB-I00 to R.R.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 and Severo Ochoa predoctoral fellowships BP-17–108 to O.E., BP‐ 20–046 to B.G. and BP-21–084 to DM].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

  • Rey, Verónica
  • Tornín, Juan
  • Alba-Linares, Juan J.
  • Robledo, Cristina
  • Murillo, Dzohara
  • Rodríguez, Aida
  • Gallego, Borja
  • Huergo, Carmen
  • Viera, Cristina
  • Braña, Alejandro
  • Astudillo, Aurora
  • Heymann, Dominique
  • Szuhai, Karoly
  • Bovée, Judith V.M.G.
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Alonso, Javier
  • Rodríguez, René
[Background]: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes are among the most common mutations detected in chondrosarcomas and may represent a therapeutic opportunity. The presence of mutated IDH (mIDH) enzymes results in the accumulation of the oncometabolite 2-HG leading to molecular alterations that contribute to drive tumour growth., [Methods]: We developed a personalized medicine strategy based on the targeted NGS/Sanger sequencing of sarcoma samples (n = 6) and the use of matched patient-derived cell lines as a drug-testing platform. The anti-tumour potential of IDH mutations found in two chondrosarcoma cases was analysed in vitro, in vivo and molecularly (transcriptomic and DNA methylation analyses)., [Findings]: We treated several chondrosarcoma models with specific mIDH1/2 inhibitors. Among these treatments, only the mIDH2 inhibitor enasidenib was able to decrease 2-HG levels and efficiently reduce the viability of mIDH2 chondrosarcoma cells. Importantly, oral administration of enasidenib in xenografted mice resulted in a complete abrogation of tumour growth. Enasidenib induced a profound remodelling of the transcriptomic landscape not associated to changes in the 5 mC methylation levels and its anti-tumour effects were associated with the repression of proliferative pathways such as those controlled by E2F factors., [Interpretation]: Overall, this work provides preclinical evidence for the use of enasidenib to treat mIDH2 chondrosarcomas., Supported by the Spanish Research Agency/FEDER (grants PID2022-142020OB-I00; PID2019-106666RB-I00), the ISC III/FEDER (PI20CIII/00020; DTS18CIII/00005; CB16/12/00390; CB06/07/1009; CB19/07/00057); the GEIS group (GEIS-62); and the PCTI (Asturias)/FEDER (IDI/2021/000027)., Consorcio CIBERONC - CB16/12/00390 and Consorcio CIBERER–CB06/07/1009 and CB19/07/00057)]; the Spanish Group for Research on Sarcomas (GEIS) (grant GEIS-62 to R.R.); and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (PCTI)/FEDER (grant IDI/2021/000027 to R.R.). BG and DM were supported by Severo Ochoa predoctoral fellowships (Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER; grants BP- 20-046 and BP-21–084 respectively). CH was supported by a predoctoral fellowship from the Fundación Científca de la Asociación Española Contra el Cáncer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

  • Estupiñán, Óscar
  • Rey, Verónica
  • Tornín, Juan
  • Murillo, Dzohara
  • Gallego, Borja
  • Huergo, Carmen
  • Blanco-Lorenzo, Verónica
  • Victoria González, M.
  • Rodríguez, Aída
  • Moris, Francisco
  • Justicia González, Jessica
  • Ayllón, Verónica
  • Ramos-Mejía, Verónica
  • Bigas, Anna
  • Rodríguez, René
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor cells, including cancer stem cell subpopulations (CSC), in sarcomas. In transcriptomic and protein expression analyses, we identified NOTCH1 signaling as one of the main pro-stemness pathways repressed by EC-8042 in osteosarcomas. Overexpression of NOTCH-1 resulted in a reduced anti-tumor effect of EC-8042 in CSC-enriched 3D tumorspheres cultures. On the other hand, the depletion of the NOTCH-1 downstream target HES-1 was able to enhance the action of EC-8042 on CSCs. Moreover, HES1 depleted cells failed to recover after treatment withdrawal and showed reduced tumor growth potential in vivo. In contrast, mice xenografted with NOTCH1-overexpressing cells responded worse than parental cells to EC-8042. Finally, we found that active NOTCH1 levels in sarcoma patients was associated to advanced disease and lower survival. Overall, these data highlight the relevant role that NOTCH1 signaling plays in mediating stemness in osteosarcoma. Moreover, we demonstrate that EC-8042 is powerful inhibitor of NOTCH signaling and that the anti-CSC activity of this mithramycin analog highly rely on its ability to repress this pathway., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grant PID2019–106666RB-I00 to R.R.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 and Severo Ochoa predoctoral fellowships BP-17–108 to O.E., BP‐ 20–046 to B.G. and BP-21–084 to DM]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells

  • Tornín, Juan
  • Gallego, Borja
  • Rey, Verónica
  • Murillo, Dzohara
  • Huergo, Carmen
  • Rodríguez, Aída
  • Canal, Cristina
  • Rodríguez, René
Osteosarcoma (OS) is an aggressive bone cancer with poor prognosis, largely due to the limited effectiveness of current treatments such as doxorubicin (DX). Developing ways to overcome DX resistance is a significant clinical challenge. Here, we used two DX-resistant models to study the potential of Cold Plasma Treated Medium (PTM) to prevent DX resistance in OS. During the acquisition of the resistant phenotype upon long-term DX exposure, OS resistant cells became less proliferative, overexpressed the drug resistance-related efflux pump MDR1 and displayed a concomitant loss of SOD2 or GPX1. According to the reduced expression of these antioxidant enzymes, PTM treatment produced higher levels of oxidative express and was more effective in eradicating DX-resistant cells. Moreover, PTM reduced the expression of MDR1, thus sensitizing resistant cells to DX. These findings uncover new vulnerabilities of DX-resistant cells related with their inability to cope with excessive oxidative stress and their dependence on MDR1 that can be exploited using PTM-based treatments to provide new therapeutic approaches for the management of drug resistance in OS., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grants PID2019-106666RB-I00 and PID2022-142020OB-I00 to R.R. and PID2019- 103892RB-I00/AEI/10.13039/501100011033 to C.C.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390]; the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 to R.R. and Severo Ochoa predoctoral fellowships BP‐ 20–046 to B.G. and BP-21–084 to DM]; Fundación Científca de la Asociación Española Contra el Cáncer (AECC) (predoctoral fellowship to CH); CC belongs to SGR2022-1368 and acknowledges Generalitat de Catalunya for the ICREA Academia Award for Excellence in Research., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

  • Estupiñán, Óscar
  • Rey, Verónica
  • Tornín, Juan
  • Murillo, Dzohara
  • Gallego, Borja
  • Huergo, Carmen
  • Blanco Lorenzo, Verónica
  • González Meana, M. Victoria
  • Rodríguez Pérez, Aida
  • Moris, Francisco
  • González Miranda, Jessica
  • Ayllón, Verónica
  • Ramos-Mejía, Verónica
  • Bigas Salvans, Anna
  • Rodríguez, René
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor cells, including cancer stem cell subpopulations (CSC), in sarcomas. In transcriptomic and protein expression analyses, we identified NOTCH1 signaling as one of the main pro-stemness pathways repressed by EC-8042 in osteosarcomas. Overexpression of NOTCH-1 resulted in a reduced anti-tumor effect of EC-8042 in CSC-enriched 3D tumorspheres cultures. On the other hand, the depletion of the NOTCH-1 downstream target HES-1 was able to enhance the action of EC-8042 on CSCs. Moreover, HES1 depleted cells failed to recover after treatment withdrawal and showed reduced tumor growth potential in vivo. In contrast, mice xenografted with NOTCH1-overexpressing cells responded worse than parental cells to EC-8042. Finally, we found that active NOTCH1 levels in sarcoma patients was associated to advanced disease and lower survival. Overall, these data highlight the relevant role that NOTCH1 signaling plays in mediating stemness in osteosarcoma. Moreover, we demonstrate that EC-8042 is powerful inhibitor of NOTCH signaling and that the anti-CSC activity of this mithramycin analog highly rely on its ability to repress this pathway., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grant PID2019–106666RB-I00 to R.R.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390)] and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 and Severo Ochoa predoctoral fellowships BP-17–108 to O.E., BP‐ 20–046 to B.G. and BP-21–084 to DM].
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

  • Estupiñán, Óscar
  • Rey, Verónica
  • Tornín, Juan
  • Murillo, Dzohara
  • Gallego, Borja
  • Huergo, Carmen
  • Blanco-Lorenzo, Verónica
  • González Meana, M. Victoria|||0000-0001-9565-4899
  • Rodríguez, Aida
  • Moris, Francisco
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Ayllon, Veronica
  • Ramos-Mejía, Verónica|||0000-0002-8013-4273
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Rodríguez, René|||0000-0002-0768-7306
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor cells, including cancer stem cell subpopulations (CSC), in sarcomas. In transcriptomic and protein expression analyses, we identified NOTCH1 signaling as one of the main pro-stemness pathways repressed by EC-8042 in osteosarcomas. Overexpression of NOTCH-1 resulted in a reduced anti-tumor effect of EC-8042 in CSC-enriched 3D tumorspheres cultures. On the other hand, the depletion of the NOTCH-1 downstream target HES-1 was able to enhance the action of EC-8042 on CSCs. Moreover, HES1 depleted cells failed to recover after treatment withdrawal and showed reduced tumor growth potential in vivo. In contrast, mice xenografted with NOTCH1-overexpressing cells responded worse than parental cells to EC-8042. Finally, we found that active NOTCH1 levels in sarcoma patients was associated to advanced disease and lower survival. Overall, these data highlight the relevant role that NOTCH1 signaling plays in mediating stemness in osteosarcoma. Moreover, we demonstrate that EC-8042 is powerful inhibitor of NOTCH signaling and that the anti-CSC activity of this mithramycin analog highly rely on its ability to repress this pathway.